全文获取类型
收费全文 | 37825篇 |
免费 | 2459篇 |
国内免费 | 762篇 |
专业分类
耳鼻咽喉 | 158篇 |
儿科学 | 822篇 |
妇产科学 | 430篇 |
基础医学 | 5102篇 |
口腔科学 | 382篇 |
临床医学 | 3684篇 |
内科学 | 7402篇 |
皮肤病学 | 438篇 |
神经病学 | 1100篇 |
特种医学 | 571篇 |
外国民族医学 | 2篇 |
外科学 | 2178篇 |
综合类 | 2733篇 |
现状与发展 | 3篇 |
一般理论 | 48篇 |
预防医学 | 10556篇 |
眼科学 | 398篇 |
药学 | 2475篇 |
29篇 | |
中国医学 | 587篇 |
肿瘤学 | 1948篇 |
出版年
2024年 | 104篇 |
2023年 | 2690篇 |
2022年 | 5786篇 |
2021年 | 7511篇 |
2020年 | 5245篇 |
2019年 | 872篇 |
2018年 | 904篇 |
2017年 | 763篇 |
2016年 | 810篇 |
2015年 | 926篇 |
2014年 | 1174篇 |
2013年 | 1568篇 |
2012年 | 1158篇 |
2011年 | 1361篇 |
2010年 | 1139篇 |
2009年 | 1088篇 |
2008年 | 772篇 |
2007年 | 958篇 |
2006年 | 854篇 |
2005年 | 719篇 |
2004年 | 701篇 |
2003年 | 626篇 |
2002年 | 463篇 |
2001年 | 416篇 |
2000年 | 350篇 |
1999年 | 317篇 |
1998年 | 236篇 |
1997年 | 218篇 |
1996年 | 184篇 |
1995年 | 122篇 |
1994年 | 97篇 |
1993年 | 103篇 |
1992年 | 74篇 |
1991年 | 82篇 |
1990年 | 71篇 |
1989年 | 69篇 |
1988年 | 53篇 |
1987年 | 42篇 |
1986年 | 39篇 |
1985年 | 87篇 |
1984年 | 64篇 |
1983年 | 39篇 |
1982年 | 39篇 |
1981年 | 34篇 |
1980年 | 23篇 |
1979年 | 19篇 |
1978年 | 13篇 |
1977年 | 13篇 |
1975年 | 10篇 |
1973年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
31.
32.
33.
变形链球菌表面蛋白和葡糖基转移酶基因疫苗对唾液变形链球菌和牙菌斑的影响 总被引:2,自引:0,他引:2
目的 了解变形链球菌表面蛋白和葡糖基转移酶基因疫苗单独及联合免疫对定菌鼠唾液变链菌和牙面菌斑的影响。方法 2 8d龄 Wistar大鼠 3 6只 ,随机分为 pc DNA3 - pac组、pc DNA3 - gtf B组、pc DNA3 - pac联合pc DNA 3 - gtf B组、变形链球菌灭活全菌组、pc DNA3空载体组和 PBS液组 ,进行三次双侧颌下腺腺周注射免疫 ,建立定菌鼠模型 ,作诱龋实验 3个月。唾液变链菌计数和菌斑计分。结果 唾液变链菌菌落计数和牙面菌斑计分在 pc D-NA3与 PBS组最高 ,其次为单基因疫苗免疫组 ,联合基因疫苗和灭活全菌细胞免疫组最低 ,各组间有显著性差异 ( P<0 .0 5 )。结论 pc DNA3 - gtf B和 pc DNA3 - pac具有明显的免疫抑菌作用 ,联合基因疫苗免疫优于单基因疫苗 相似文献
34.
35.
Dengue is a mosquito-borne viral disease caused by four antigenically distinct serotypes of dengue viruses (DENVs). This disease, which is prevalent in over a hundred tropical and sub-tropical countries of the world, represents a significant global public health problem. A tetravalent dengue vaccine capable of protecting against all four DENV serotypes has been elusive so far. Current efforts are focused on producing a tetravalent vaccine by mixing four monovalent vaccine components. In this work, we have utilized a discrete carboxy-terminal region of the major DENV envelope (E) protein, known as domain III (EDIII), which mediates virus entry into target cells and contains multiple serotype-specific neutralizing epitopes, to create a chimeric tetravalent antigen. This antigen derived by in-frame fusion of the EDIII-encoding sequences of the four DENV serotypes was expressed using a replication-defective recombinant human adenovirus type 5 (rAdV5) vaccine vector. This rAdV5 vector induced cell-mediated immune responses and virus-neutralizing antibodies specific to each of the four DENVs in mice. Interestingly, anti-AdV5 antibodies did not suppress the induction of DENV-specific neutralizing antibodies. We observed that anti-AdV5 antibodies in the sera of immunized mice could promote uptake of a rAdV5-derived reporter vector into U937 cells, suggesting that pre-existing immunity to AdV5 may in fact facilitate the uptake of rAdV5 vectored vaccines into antigen presenting cells. This work presents an alternative approach to developing a single component tetravalent vaccine that bypasses the complexities inherent in the currently adopted four-in-one physical mixture approach. 相似文献
36.
Z. Peng Q. Liu Q. Wang E. Rector Y. Ma R. Warrington 《Clinical and experimental allergy》2007,37(7):1040-1048
BACKGROUND: Immunotherapy with anti-IgE antibodies for treatment of allergy is promising but a short half-life and extremely high cost limit its application. OBJECTIVE: We sought to develop IgE vaccines that induce longer-lasting auto-antibodies to neutralize self-IgE as an alternative therapy. METHODS: The vaccine was made by conjugating three synthetic peptides corresponding to human IgE receptor-binding sites to a carrier, hepatitis B surface antigen. To test the immunogenicity of the vaccine, rats were immunized with the vaccine or hepatitis B surface antigen as control. Serum IgG titres to human IgE and the IgE of other species were measured. The inhibition by rat antisera of the binding of human IgE to its receptor was assessed by ELISA, flow cytometry analysis, and passive cutaneous anaphylaxis (PCA), and its ability to recognize receptor-bound IgE was examined. The in vivo effect of the vaccine was evaluated in trichosanthin-sensitized mice and rats. In the preventative study, vaccination started before sensitization commenced, while in the treatment study, vaccination started after sensitization. Sensitized mice and rats receiving injections of the carrier served as controls. Trichosanthin-specific IgE was measured using PCA. RESULTS: Sera from vaccine-immunized rats contained high titre antibodies that reacted with soluble and plate-bound but not with receptor-bound human IgE; they also reacted with mouse, rat, and dog IgE. Furthermore, the sera inhibited the binding of human IgE to its receptor in a dose-dependent manner. In preventative and treatment studies, serum trichosanthin-specific IgE levels were significantly reduced in vaccinated groups compared with controls. CONCLUSION: Antibodies against self-IgE can be induced by IgE peptide-based vaccines, which are effective in preventing the increase of IgE and in down-regulating IgE in sensitized animals. 相似文献
37.
采用微量乙肝疫苗(总剂量为6μg)对HBV高流行区居民进行随机对照研究,免疫Ⅰ组(疫苗<8℃保存)T12抗体阳转率和保护率分别为90.8%和87.0%,和对照组相比,差异显著(P均<0.001);和常规剂量(总剂量90μg)比,其抗体阳转率和保护率基本相同。提示HBV高流行区可用微量乙肝苗代替常量乙肝苗进行预防接种。免疫Ⅰ组和免疫Ⅱ组(乙肝疫苗室温保藏28℃±)免疫效果和保护率基本相同,认为室温条件下乙肝疫苗6个月内效价不变。 相似文献
38.
重组酵母乙肝疫苗免疫效果研究 总被引:36,自引:0,他引:36
目的研究重组酵母乙肝疫苗对青少年学生的免疫效果。方法同时对365名乙肝病毒血清学指标(HBV-M)不同感染状况的学生进行免疫监测。随机分为两组,A组:183人,接种剂量10-5-5(μg),B组:182人,接种剂量5-5-5(μg),用ELISA法,在全自动酶标分析仪上测定。结果1.重组酵母乙肝疫苗对青少年免疫效果良好,抗-HBs阳性率达97%以上;2.对HBV-M不同感染状况的学生,免疫后均无不良反应。结论HBV易感者和感染者接种疫苗后免疫效果均好。在青少年中普种乙肝疫苗可不筛查HBV-M。 相似文献
39.
水痘疫苗接种的成本效益 总被引:4,自引:0,他引:4
水痘是一种常见的急性、高传染性的疾病 ,可感染儿童、成人。 1974年日本首先研制成功Oka株水痘减毒活疫苗 ,1984年世界卫生组织批准水痘减毒活疫苗用于婴幼儿预防接种 ,许多国家陆续开展了水痘疫苗预防接种 ,不仅能取得良好的防病效果 ,而且可较大地减轻疾病负担。对儿童、青少年、成人、育龄期妇女和免疫功能抑制患者分别进行的经济学评价表明 ,接种水痘疫苗具有较好的成本效益结果。 相似文献
40.
Robert S. Mathias 《Pediatric nephrology (Berlin, Germany)》1997,11(3):355-357
. This is a report of unexplained anemia that persisted for 4 months in an adolescent renal transplant patient receiving immunosuppression
that included prednisone, tacrolimus, and mycophenolate mofetil. This patient required monthly blood transfusions for fatigue,
palpitations, and hematocrit levels between 15% and 17%. In addition, his posttransplant course was notable for the development
of insulin-dependent diabetes mellitus. While receiving low-dose prednisone, he was switched from tacrolimus to cyclosporin
and tapered off insulin injections over the next 2 months. At 4.5 months post-transplantation, further diagnostic evaluation
was suggestive of parvovirus B19 infection as the cause for our patient’s chronic anemia. After testing negative for serum-specific
parvovirus B19 IgM and IgG antibodies, parvovirus B19 infection was detected in blood by the polymerase chain reaction. Treatment
with intravenous immunoglobulin (1 g/kg per day × 2 days) resulted in normalization of both his reticulocyte count and hematocrit
within 6 weeks. At 4 months after receiving the immunoglobulin infusion, he has maintained a normal hematocrit level and stable
renal function without requiring further blood transfusions.
Received August 23, 1996; received in revised form and accepted November 20, 1996 相似文献